Although RTK inhibitors, especially FLT3 inhibitor-quizartinib, demonstrate single-agent efficacy by inducing complete remission in cancer patients, their utility is limited to FLT3-mutant AML patients [2,3]. The gene discussed is FLT3; the disease is acute myeloid leukemia.